Clarivate PLC CLVT
We take great care to ensure that the data presented and summarized in this overview for CLARIVATE Plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLVT
View all-
Leonard Green & Partners, L.P. Los Angeles, CA117MShares$506 Million10.99% of portfolio
-
Clarkston Capital Partners, LLC Bloomfield Hills, MI74.5MShares$323 Million5.82% of portfolio
-
Exor N.V. Amsterdam, P767.3MShares$292 Million100.0% of portfolio
-
Impactive Capital LP New York City, NY43MShares$187 Million7.74% of portfolio
-
Fil LTD Hamilton, D022.3MShares$97 Million0.09% of portfolio
-
Black Rock Inc. New York, NY20.4MShares$88.5 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX16.6MShares$72 Million0.02% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il12.8MShares$55.4 Million0.01% of portfolio
-
Atairos Group, Inc. Bryn Mawr, PA12.3MShares$53.2 Million2.17% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.1MShares$52.5 Million0.01% of portfolio
Latest Institutional Activity in CLVT
Top Purchases
Top Sells
About CLVT
Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.
Insider Transactions at CLVT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 07
2025
|
Wendell E. Pritchett Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+27.94%
|
-
|
May 07
2025
|
Suzanne Heywood Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+43.44%
|
-
|
May 07
2025
|
Andrew Miles Snyder Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+20.5%
|
-
|
May 07
2025
|
Jane L Okun Bomba Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+16.0%
|
-
|
May 07
2025
|
Saurabh Saha Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+25.31%
|
-
|
May 07
2025
|
Valeria Alberola Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,473
+30.22%
|
-
|
May 06
2025
|
Wendell E. Pritchett Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,497
-13.22%
|
$37,988
$4.17 P/Share
|
May 06
2025
|
Suzanne Heywood Director |
SELL
Payment of exercise price or tax liability
|
Direct |
11,809
-49.74%
|
$47,236
$4.17 P/Share
|
May 06
2025
|
Andrew Miles Snyder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,732
-1.5%
|
$6,928
$4.17 P/Share
|
May 06
2025
|
Jane L Okun Bomba Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,722
-1.02%
|
$6,888
$4.17 P/Share
|
May 06
2025
|
Saurabh Saha Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,974
-6.06%
|
$19,896
$4.17 P/Share
|
May 06
2025
|
Valeria Alberola Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,042
-10.47%
|
$24,168
$4.17 P/Share
|
May 06
2025
|
Angelakis Michael J Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,946
-8.82%
|
$19,784
$4.17 P/Share
|
May 01
2025
|
Henry Levy President, LS&H |
SELL
Payment of exercise price or tax liability
|
Direct |
39,788
-5.03%
|
$159,152
$4.29 P/Share
|
Mar 31
2025
|
Andrew Miles Snyder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
840
-0.72%
|
$2,520
$3.93 P/Share
|
Mar 31
2025
|
Andrew Miles Snyder Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,040
+10.09%
|
$39,120
$3.93 P/Share
|
Mar 31
2025
|
Jane L Okun Bomba Director |
SELL
Payment of exercise price or tax liability
|
Direct |
404
-0.24%
|
$1,212
$3.93 P/Share
|
Mar 31
2025
|
Jane L Okun Bomba Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,315
+4.13%
|
$21,945
$3.93 P/Share
|
Mar 15
2025
|
Henry Levy President, LS&H |
BUY
Grant, award, or other acquisition
|
Direct |
242,130
+23.45%
|
-
|
Mar 15
2025
|
Bar Veinstein President, A&G |
BUY
Grant, award, or other acquisition
|
Direct |
242,130
+17.28%
|
-
|
Last 12 Months Summary
Open market or private purchase | 4.12M shares |
---|---|
Grant, award, or other acquisition | 4.15M shares |
Bona fide gift | 239K shares |
Payment of exercise price or tax liability | 395K shares |
---|---|
Open market or private sale | 198K shares |
Other acquisition or disposition | 30.3K shares |